Home  »  Company  »  Dr. Agarwal's Ey  »  Quotes  »  Notes to Account
Enter the first few characters of Company and click 'Go'

Notes to Accounts of Dr. Agarwal's Eye Hospital Ltd.

Mar 31, 2018

1 CORPORATE INFORMATION

Dr. Agarwal''s Eye Hospital Limited (‘the Company'') was incorporated on April 22, 1994 and is primarily engaged in providing eye care and related services. As at 31 March 2018, the Company is operating in 22 locations in India. Dr. Agarwal''s Health Care Limited is the holding Company as at 31 March 2018.

2 APPLICATION OF NEW AND REVISED IND AS

All the Indian Accounting Standards issued and notified by the Ministry of Corporate Affairs under the Companies (Indian Accounting Standards) Rules, 2015 (as amended) till the financial statements are authorised have been considered in the preparing these financial statements. There is no other Indian Accounting Standard that has been issued as of that date but was not mandatorily effective.

Recent Standards notified but not effective:

Ind AS 115 - “Revenue from Contracts with Customers”:

On 28 March 2018, the Ministry of Corporate Affairs (MCA), notified Ind AS 115, Revenue from Contracts with Customers, as part of the Companies (Indian Accounting Standards) Amendment Rules, 2018. The new standard is based on IFRS 15, Revenue from Contracts with Customers. The standard is effective for the accounting periods commencing on or after 1 April 2018.

Ind AS 115 replaces Ind AS 11 Construction contracts and Ind AS 18 Revenue. The core principle of Ind AS 115 is that an entity recognises revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This core principle is delivered in a five-step model framework:

- Identify the contract(s) with a customer - assess whether the contract is within the scope of Ind AS 115. ‘Customer'' has now been defined.

- Identify the performance obligations in the contract - determine whether the goods and services in a contract are distinct.

- Determine the transaction price - transaction price will include fixed, variable and non cash considerations.

- Allocate the transaction price to the performance obligations in the contract - allocation based on a stand-alone selling price basis using acceptable methods.

- Recognise revenue when (or as) the entity satisfies a performance obligation - i.e. recognise revenue at a point in time or over a period of time based on performance obligations.

The Company is evaluating the requirements of the standards, and the transition effects on the financial statements.”

Appendix B to Ind AS 21, Foreign currency transactions and advance consideration:

On March 28, 2018, the Ministry of Corporate Affairs (“MCA”) has notified the Companies (Indian Accounting Standards) Amendment Rules, 2018 containing Appendix B to Ind AS 21, Foreign currency transactions and advance consideration which clarifies the date of the transaction for the purpose of determining the exchange rate to use on initial recognition of the related asset, expense or income, when an entity has received or paid advance consideration in a foreign currency. The amendment will come into force from April 1, 2018. The Company is evaluating the effect of this on the financial statements.

Standards yet to be notified:

Ind AS 116 - “Leases”:

On 18 July 2017, the Accounting Standards Board (ASB) of the Institute of Chartered Accountants of India (ICAI) issued an Exposure Draft (ED) of Ind AS 116, Leases. Ind AS 116 is largely converged with IFRS 16. When notified, Ind AS 116 will replace Ind AS 17 Leases.

Ind AS 116 sets out a comprehensive model for identification of lease arrangements and their treatment in the financial statements of the lessor and lessee. Ind AS 116 applies a control model for the identification of leases, distinguishing between leases and service contracts on the basis of whether there is an identified asset controlled by the customer. The Company is evaluating the requirement of the standard and the effect on the financial statements upon notification is being evaluated.

3. Credit period and risk

Significant portion of the Company''s business is against receipt of advance. Credit is provided mainly to Insurance Companies, Corporate customers and Government Undertakings. The Insurance Companies are required to maintain minimum reserve levels and preapprove the insurance claim, Government undertakings and the Corporate Customers are enterprises with high credit ratings. Accordingly, the Company''s exposure to credit risk in relation to trade receivables is low.

Trade receivables are non-interest bearing and are generally on terms of upto 30 days. Of the Trade Receivable as at 31 March 2018, Rs. 725.60 lakhs (As at 31 March 2017: Rs.712.04 lakhs; As at 1 April 2016 : Rs.620.22 lakhs) are due from seven of the Company''s customers i.e having more than 5% of the total outstanding trade receivable balance. There are no other customers who represent more than 5% of the total balance of trade receivables.

No trade receivable are due from directors or other officers of the Company either severally or jointly with any other person. Nor any trade receivable are due from firms or private companies respectively in which any director is a partner, a director or a member.

4. Expected credit loss allowance

The Company has used a practical expedient by computing the expected loss allowance for trade receivables based on provision matrix. The provision matrix takes into account the historical credit loss experience and adjustments for forward looking information. The expected credit loss allowance is based on the ageing of the days the receivables are due and the rates as given in the provision matrix, considering the amounts due from the government undertakings and the other undertakings.

5. Terms / rights attached to Equity Shares :

The Company has only one class of equity shares having a par value of Rs.10. Each holder is entitled to one vote per equity share. Dividends are paid in Indian Rupees. Dividend proposed by the Board of Directors, if any, is subject to the approval of the shareholders at the Annual General Meeting except in case of interim dividend. Repayment of capital will be in accordance with the terms of the Articles of Association and in proportion to the number of equity shares held.

The Board of Directors, at their meeting held on 28 May 2018, have proposed a final dividend of Rs.1.20 per equity share, aggregating to Rs.56.40 lakhs, for the year ended 31 March 2018. The dividend proposed by the Board of Directors is subject to the approval of shareholders at the ensuing Annual General Meeting.

6. I n respect of the year ended 31 March 2018, the directors propose that a dividend of Rs.1.20 per share be paid on fully paid equity shares. This equity dividend is subject to approval by shareholders at the Annual General Meeting and has not been included as a liability in these financial statements. The proposed equity dividend is payable to all holders of fully paid equity shares.

(i) The details of Security provided against the Term Loans are as follows:

- Extension of first charge on the entire Property, Plant and Equipment of the Company and first charge on the assets to be created out of the Term Loan.

- Extension of equitable mortagage on a property owned by Orbit International.

- Extension of first charge on the entire Fixed assets of the company and first charge on the assets to be created out of the Term Loan.

- Pledge of 1,350,000 Shares of the Company held by Dr. Agarwal''s Health Care Limited.

- Corporate Guarantee provided by Dr. Agarwal''s Health Care Limited and Orbit International.

- Personal Guarantees of Dr. Amar Agarwal, Dr. Athiya Agarwal, Dr. Adil Agarwal, Dr. Anosh Agarwal, Dr. Ashar Agarwal, Dr. Ashwin Agarwal, being the promoter and relatives of the promoter.

(ii) The loans are secured by hypothecation of respective vehicles financed by the Banks.

(iii) The loans are secured by hypothecation of surgical equipments.

Whilst the provision as at 31 March 2018 is considered as short term in nature, the actual outflow with regard to said matters depends on the exhaustion of remedies available under the law based on various developments. No recoveries are expected against the provision.

(ii) The Cash credit facility availed by the Company as at 31 March 2018 is secured by the following:

- Hypothecation of all the current assets of the Company.

- Extension of equitable mortagage on a property owned by Orbit International.

- Pledge of 1,350,000 shares of the Company held by Dr. Agarwal''s Health Care Limited.

- Corporate Guarantee provided by Dr. Agarwal''s Health Care Limited and Orbit International.

- Personal Guarantees of Dr. Amar Agarwal, Dr. Athiya Agarwal, Dr. Adil Agarwal, Dr. Anosh Agarwal, Dr. Ashar Agarwal and Dr. Ashwin Agarwal being the promoter and relatives of the promoter.

(i) Based on Professional Advice / Management''s assessment of all the above claims, the Company expects a favourable decision in respect of the above claims and hence no specific provision has been considered for the above claims. Also refer Note 18.1.

(ii) The amounts shown above represent the best possible estimates arrived at on the basis of the available information. The uncertainties and possible reimbursement are dependent on the outcome of the various legal proceedings which have been initiated by the Company or the Claimants, as the case may be and, therefore, cannot be predicted accurately.

7. Employee Benefits

7.1 Defined Contribution plans

(a) The Company makes Provident and Pension Fund contributions, which is a defined contribution plan, for qualifying employees. Additionally, the Company also provides, for covered employees, health insurance through the Employes State Insurance scheme. Under the Schemes, the Company is required to contribute a specified percentage of the payroll costs to fund the benefits. The contributions payable to these plans by the Company are at rates specified in the rules of the schemes.

7.2 Defined benefit plans

The Company operates a gratuity plan covering qualifying employees. The benefit payable is calculated as per the Payment of Gratuity Act, 1972 and the benefit vests upon completion of five years of continuous service and once vested it is payable to employees on retirement or on termination of employment. In case of death while in service, the gratuity is payable irrespective of vesting. The Company makes annual contribution to the group gratuity scheme administered by the Life Insurance Corporation of India.

In respect of the plan, the most recent actuarial valuation of the plan assets and the present value of the defined benefit obligation were carried out as at March 31, 2018 by Mr. Srinivasan Naga Subramanian, Fellow of the Institute of Actuaries of India. The present value of the defined benefit obligation, and the related current service cost and paid service cost, were measured using the projected unit cost credit method.

(i) The current service cost and interest expense for the year are included in Note 27 - “Employee Benefit Expenses” in the statement of profit & loss under the line item “Contribution to Provident and Other Funds”

(ii) The remeasurement of the net defined benefit liability is included in other comprehensive income.

(i) The plan assets comprise insurer managed funds. None of the assets carry a quoted market price in active market or represent the entity''s own transferable financial instruments or property occupied by the entity.

(f) The Actual return on plan asset for the year ended 31 March 2018 was Rs.9.70 lakhs (For the year ended - 31 March 2017: Rs.8.86 lakhs).

(g) Actuarial assumptions Investment Risk:

The present value of defined benefit plan liability is calculated using a discount rate which is determined by reference to the prevailing market yields of Indian government securities as at the balance sheet date for the estimated term of the obligations.

Interest Risk:

A decrease in the yield of Indian government securities will increase the plan liability.

Longevity Risk

The present value of the defined benefit plan liability is calculated by reference to the best estimate of the mortaility of plan participants both during and after their employment. An increase in the life expectancy of the plan participants will increase the plan''s liability.

Salary Risk:

The present value of the defined benefit plan liability is calculated by reference to the future salaries. In particular, there is a risk for the Company that any adverse salary growth can result in an increase in cost of providing these benefits to employees in future.

1. The discount rate is based on the prevailing market yields of Indian Government securities as at balance sheet date for the estimated term of the obligation.

2. The estimates of future salary increases considered takes into account the inflation, seniority, promotion and other relevant factors.

3. In order to protect the capital and optimize returns within acceptable risk parameters, the plan assets are maintained with an insurer managed fund (maintained by the Life Insurance Corporation (“LIC”) and is well diversed.

Sensitivity Analysis

The benefit obligation results of such a scheme are particularly sensitive to discount rate, longevity risk, salary growth and employee attrition, if the plan provision do provide for such increases on commencement of pension.

These sensitivities have been calculated to show the movement in defined benefit obligation in isolation and assuming there are no other changes in market conditions at the accounting date. The sensitivity analysis presented above may not be representative of the actual change in the defined benefit obligations as it is unlikely that the change in assumptions would occur in isolation of one another as some of the assumptions may be correlated.

Furthermore in presenting the above sensitivity analysis the present value of defined benefit obligation has been calculated using the projected unit credit method at the end of the reporting period which is the same as that applied in calculating the defined benefit obligation liability recognised in the balance sheet.

There is no change in the methods and assumptions used in preparing the sensitivity analysis from the prior years.

(h) Asset Liability Matching Strategies

The Company has purchased insurance policy, which is basically a year-on-year cash accumulation plan in which the interest rate is declared on yearly basis and is guaranteed for a period of one year. The insurance Company, as part of the policy rules, makes payment of all gratuity liability occurring during the year (subject to sufficiency of funds under the policy). The policy, thus, mitigates the liquidity risk. However, being a cash accumulation plan, the duration of assets is shorter compared to the duration of liabilities. Thus, the Company is exposed to movement in interest rate (in particular, the significant fall in interest rates, which should result in a increase in liability without corresponding increase in the asset).

(i) Effect of Plan on Entity’s Future Cash Flows

A) Funding Arrangements and Funding Policy

The Company has purchased an insurance policy to provide for payment of gratuity to the employees. Every year, the insurance Company carries out a funding valuation based on the latest employee data provided by the Company. Any deficit in the assets arising as a result of such valuation is funded by the Company.

B) The Company expects to make a contribution of '' 45 lakhs during the next financial year.

C) The weighted average duration of the benefit obligation at March 31, 2018 is 3.05 years (as at March 31, 2017 is 3.05 years).

(i) The Company accounts for costs incurred by / on behalf of the Related Parties based on the actual invoices / debit notes raised and accruals as confirmed by such related parties. The Related Parties have confirmed to the Management that as at 31 March 2018 and 31 March 2017, there are no further amounts payable to / receivable from them, other than as disclosed above. The Company incurs certain costs on behalf of other companies in the group. These costs have been allocated/recovered from the group companies on a basis mutually agreed to with the group companies.

(ii) Dr. Agarwal''s Health Care Limited has provided Corporate Guarantees amounting to Rs.2,714 lakhs to SBI for the loans taken by the Company. Further, 1,350,000 Equity Shares held by Dr. Agarwal''s Health Care Limited in the Company has been pledged as one of the collateral securities with SBI, for the loans taken by the Company to the extent of Rs.2,714 lakhs.

(iii) The Company has provided comfort letter to HDFC Bank in respect of the Equipment Loans and Cash Credit facility availed by the Dr. Agarwal''s Health Care Limited, the Holding Company.

(v) Represents transactions carried out with Senses Pharmaceuticals Limited through its dealer.

Notes:

(i) Excludes gratuity and compensated absences which cannot be separately identifiable from the composite amount advised by the actuary.

(ii) Also Refer Note 17(i) and Note20(ii).

(iii) The remuneration payable to key management personnel is determined by the nomination and remuneration committee having regard to the performance of individuals and market trends.

(iv) There were no balances outstanding to be paid / recevied as at the year end.

(i) The amounts outstanding are unsecured and will be settled in cash. No guarantees have been given or received. There have been no instances of amounts due to or due from related parties that have been written back or written off or otherwise provided for during the year.

8. Segment Reporting

The Company is engaged in providing eye care and related services provided from its hospitals which are located in India. Based on the “management approach” as defined in Ind-AS 108 - Operating Segments, the Chief Operating Decision Marker (CODM) evaluates the Company''s performance and allocates resources based on an analysis of various performance indicators by the overall business segment, i.e. Eye care related sales and services.

As the allocation of resources and profitability of the business is evaluated by the CODM on an overall basis, with evaluation into individual categories to understand the reasons for variations, no separate segments have been identified. Accordingly no additional disclosure has been made for the segmental revenue, segmental results and the segmental assets & liabilities.”

9. Operating Lease

The Company has entered into operating lease agreements primarily for Hospital premises. An amount of Rs.1,717.98 lakhs (Previous Year - Rs.1,644.09 lakhs) has been debited to the Statement of Profit and Loss towards lease rentals and other charges for the current year. The leases are non - cancellable for periods of 3 to 12 years and may be renewed based on mutual agreement of the parties.

10. Financial Instruments

10.1 Capital Management

The Company manages capital risk in order to maximize shareholders'' profit by maintaining sound/optimal capital structure. For the purpose of the Company''s capital management, capital includes equity share Capital and Other Equity and Debt includes Borrowings and Other Financial Liabilities net of Cash and bank balances. The Company monitors capital on the basis of the following gearing ratio. There is no change in the overall capital risk management strategy of the Company compared to last year.

The management assessed that fair value of cash and cash equivalents, trade receivables, loans, borrowings, trade payables and other current financial assets and liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments

The fair value of the financial assets and liabilities is included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

The following methods and assumptions were used to estimate the fair value/amortized cost

1) Long-term fixed-rate receivables/borrowings are evaluated by the Company based on parameters such as interest rates, specific country risk factors, individual losses and creditworthiness of the receivables

2) The fair value of unquoted instruments, loans from banks and other financial liabilities, as well as other non-current financial liabilities are estimated by discounting future cash flows using rates currently available for debt on similar terms, credit risk and remaining maturities. In addition to being sensitive to a reasonably possible change in the forecast cash flows or discount rate, the fair value of the unquoted instruments is also sensitive to a reasonably possible change in the growth rates. The valuation requires management to use unobservable inputs in the model, of which the significant unobservable inputs are disclosed in the tables below. Management regularly assesses a range of reasonably possible alternatives for those significant unobservable inputs and determines their impact on the total fair value.

3) Fair values of the Company''s interest-bearing borrowings and loans are determined by using DCF method using discount rate that reflects the issuer''s borrowing rate as at the end of the reporting period. The own non-performance risk as at March 31, 2018 was assessed to be insignificant.

Fair Value Hierarchy

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3: Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).

There were no items of financial assets or financial liabilities which were valued at fair value as of 31 March 2018, 31 March 2017 and 1 April 2016.

10.2 Financial Risk Management Framework

The Company''s board of directors has overall responsibility for the establishment and oversight of the Company''s risk management framework. The Company manages financial risk relating to the operations through internal risk reports which analyse exposure by degree and magnitude of risk.

The Company''s activities expose it to a variety of financial risks: liquidity risk, credit risk and market risk (including interest rate risk and other price risk). The Company''s primary risk management focus is to minimize potential adverse effects of market risk on its financial performance. The Company''s risk management assessment and policies and processes are established to identify and analyze the risks faced by the Company, to set appropriate risk limits and controls, and to monitor risks and compliance with the same. Risk assessment and management policies and processes are reviewed regularly to reflect changes in market conditions and the Company''s activities. The Board of Directors and the Audit Committee is responsible for overseeing the Company''s risk assessment and management policies and processes.

(a) Liquidity Risk Management :

Liquidity risk refers to the risk that the Company cannot meet its financial obligations as they become due. The Company manages its liquidity risk by ensuring as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risk to the Company''s reputation. The Company maintains adequate reserves and banking facilities, and continuously monitors the forecast and actual cash flows by matching maturing profiles of financial assets and financial liabilities in accordance with the approved risk management policy of the Company periodically. The Company believes that the working capital (including banking limits not utilised) and its cash and cash equivalent are sufficient to meet its short and medium term requirements.

Liquidity and Interest Risk Tables :

The following tables detail the Company''s remaining contractual maturity for its non-derivative financial liabilities with agreed repayment periods. The tables include both interest and principal cash flows.

To the extent that interest flows are floating rate, the undiscounted amount is derived from interest rate curves at the end of the reporting period. The contractual maturity is based on the earliest date on which the Company may be required to pay.

(b) Credit Risk:

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations. Credit risk encompasses of both, the direct risk of default and the risk of deterioration of creditworthiness as well as concentration of risks. Financial instruments that are subject to concentrations of credit risk principally consist of trade receivables, cash and cash equivalents, bank deposits and other financial assets. None of the other financial instruments of the Company result in material concentration of credit risk. Credit risk is controlled by analysing credit limits and creditworthiness of customers on a continuous basis to whom the credit has been granted after obtaining necessary approvals for credit.

The carrying amount of the financial assets recorded in these financial statements, grossed up for any allowance for losses, represents the maximum exposures to credit risk.

Trade receivables: The Company''s exposure to credit risk is influenced mainly by the individual characteristics of each customer. The demographics of the customer, including the default risk of the industry and credit history, also has an influence on credit risk assessment. Refer Note 12 and Note 23 for the details in respect of revenue and receivable from top customers.

Credit risk on current investments, cash & cash equivalent and derivatives is limited as the Company generally transacts with banks and financial institutions with high credit ratings assigned by international and domestic credit rating agencies. Investments primarily include investment in fixed deposits.

(c) Market Risk :

Market risk is the risk of loss of any future earnings, in realizable fair values or in future cash flows that may result from adverse changes in market rates and prices (such as interest rates and foreign currency exchange rates) or in the price of market risk sensitive instruments as a result of such adverse changes in market rates and prices. Market risk is attributable to all market risk-sensitive financial instruments, all foreign currency receivables and payables and all short-term and long-term debt. The Company is exposed to market risk primarily related to foreign exchange rate risk and interest rate risk and the market value of its investments. Thus, the Company''s exposure to market risk is a function of investing and borrowing activities and revenue generating and operating activities in foreign currencies.

(c.1) Interest rate risk:

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company''s exposure to the risk of changes in market interest rates relates primarily to the Company''s debt obligations with floating interest rates.

The Company’s management monitors the interest fluctuations, if any, and accordingly, take necessary steps to mitigate any interest rate risk.

(c.2) Foreign Currency Risk Management :

The Company undertakes transactions denominated in foreign currencies and consequently, exposures to exchange rate fluctuations arises. The Company has not entered into any derivate contracts during the year ended 31 March 2018 and there are no outstanding contracts as at 31 March 2017.

Foreign Currency sensitivity analysis:

The following table details the Company''s sensitivity to a 5% increase and decrease in INR against the relevant foreign currencies. 5% is the rate used in order to determine the sensitivity analysis considering the past trends and expectation of the management for changes in the foreign currency exchange rate. The sensitivity analysis includes the outstanding foreign currency denominated monetary items and adjusts their translation at the period end for a 5% change in foreign currency rates. A positive number below indicates an increase in profit/decrease in loss and increase in equity where the INR strengthens 5% against the relevant currency. For a 5% weakening of the INR against the relevant currency, there would be a comparable impact on the profit or loss and equity and balance below would be negative.

This is mainly attributable to the exposure of receivable and payable outstanding in the above mentioned currencies to the Company at the end of the reporting period.

10.3 Fair value of financial assets and financial liabilities that are not measured at fair value (but fair value disclosures are required)

The Management considers that the carrying amount of financial assets and financial liabilities recognized in the financial statements approximate their fair values.

10.4 Offsetting of financial assets and financial liabilities

The Company has not offset financial assets and financial liabilities.

11. First-time adoption - mandatory exceptions, optional exemptions and reconciliations

These financial statements, as at and for the year ended 31 March 2018, have been prepared in accordance with Ind AS. For the purpose of transition to Ind AS, the Company has followed the guidance prescribed in Ind AS 101 - First Time adoption of Indian Accounting Standard, with 1 April 2016 as the transition date and IGAAP as the previous GAAP.

The transition to Ind AS has resulted in changes in the presentation of the financial statements, disclosures in the notes there to and accounting policies and principles. The accounting policies set out in Note 3 have been applied in preparing the financial statements for the year ended 31 March 2018 and the comparative information. An explanation of how the transition from previous GAAP to Ind AS has affected the Company''s Balance Sheet, Statement of Profit and Loss and cash flow, Optional exemptions and certain exceptions on first time adoption of Ind AS availed in accordance with Ind AS 101 have been set out below:

11.1 Mandatory Exceptions and Optional Exemptions

(a) Deemed Cost for Property, plant and equipment and intangible assets

The Company has elected to continue with the carrying value of all of its property, plant and equipment and intangible assets recognized as at 1 April 2016 (transition date) measured as per the previous Indian GAAP (‘I GAAAP'') and use that carrying value as its deemed cost as of the transition date.

(b) Classification and measurement of financial assets

The company has opted not to apply EIR principles retrospectively and thus opted to consider the carrying cost of financial asset as its amortised cost as at transition date.

Key Sources of estimation uncertainty

The estimates at 1 April 2016 and at 31 March 2017 are consistent with those made for the same dates in accordance with previous GAAP (after adjustments to reflect any differences in accounting policies). The estimates used by the Company to present these amounts in accordance with Ind AS reflect conditions at 1 April 2016, the date of transition to Ind AS and as of 31 March 2017.

(a) Under previous GAAP, there was no concept of other comprehensive income. Under Ind AS, specified items of income, expense, gains or losses are required to be presented in other comprehensive income.

(b) Under previous GAAP, dividends on equity shares recommended by the board of directors after the end of reporting period but before the financial statements were approved for issue were recognised in the financial statements as a liability. Under Ind AS, such dividends are recognised when declared by the members in annual general meeting. Effect of this change is increase in total equity by Rs.45.25 lakhs as at 1 April 2016 (Rs. NIL as at 31 March 2017), decrease in Provisions - Current by Rs.45.25 lakhs as at 1 April 2016 (Rs. NIL as at 31 March 2017).

(c) Under previous GAAP, actuarial gains and losses were recognised in profit and loss. Under Ind AS, the actuarial gains and losses form part of remeasurement of net defined liability/asset which is recognised in other comprehensive income. Consequently, the tax effect of the same has also been recognised in other comprehensive income. The actuarial loss for the year ended 31 March 2017 was Rs.40.75 lakhs and tax effect was Rs.14.10 lakhs and deferred tax liabilities reduced by Rs.14.10 lakhs as at 31 March 2017.

(d) Under previous GAAP, security deposits are carried at cost. Under Ind AS, these are carried at amortized cost. The effect of this change is decrease in financial assets by Rs.257.75 lakhs as at 31 March 2017 (decrease by Rs.310.06 lakhs as at 1 April 2016) and increase in other current assets by Rs.216.94 lakhs as at 31 March 2017 (increase by Rs.267.67 lakhs as at 1 April 2016) and decrease in total equity by Rs.42.39 lakhs as at 31 March 2016. There had been increase in other income by Rs.52.30 lakhs and other expenses by Rs.50.73 lakhs for the year ended 31 March 2017 and consequently decrease in deferred tax liabilities by Rs.214.20 lakhs as at 31 March 2017 (Rs. NIL as at 1 April 2016).

(e) Under previous GAAP, Borrowing cost and processing fees related to loans and financial liabilities were charged off to the statement of profit and loss. Under Ind AS, the Company needs to measure the borrowings at fair value using Effective interest rate (EIR) also considering the Upfront fees and Processing fees paid and any interest free loan at the time of obtaining the borrowings. The net effect of change is decrease in borrowings under non current liabilities by Rs.17.55 lakhs as at 31 March 2017 (decrease by Rs.24.11 lakhs as at 1 April 2016) and increase in total equity by Rs.17.55 lakhs as at 31 March 2017 (Rs. 24.11 lakhs as at 1 April 2016). There had been increase in finance cost by Rs.6.56 lakhs and decrease in deferred tax liabilities by Rs.6.11 lakhs as at 31 March 2017 (increase by Rs.8.39 lakhs as at 1 April 2016).

(f) Under previous GAAP, the Company made provision for doubtful debts for Trade Receivables based on the ageing analysis and individual debtor assessment of recoverability. Under IND AS the impairment model of financial asset is based on Expected Credit Loss model. Accordingly, the Company has provided loss allowance based on Expected credit loss and as a result trade receivables has decreased by Rs.66.97 lakhs as at 31 March 2017 (decreased by Rs.148.37 lakhs as at 1 April 2016). Retained earnings under other Equity decreased by Rs.148.37 lakhs as at 1 April 2016. Consequently, allowance for expected credit losses under other expenses decreased by Rs.81.40 lakhs for the year ended 31 March 2017.

(g) Under previous GAAP the deferred tax was accounted based on timing differences impacting the Statement of Profit and Loss for the period. Deferred tax under Ind AS has been recognised for temporary differences between tax base and the book base of the relevant assets and liabilities. As a result thereof, the deferred tax asset has increased by Rs.31.22 lakhs as at 31 March 2017 (increased by Rs.57.67 lakhs as at 1 April 2016).

(h) The previous GAAP figures have been reclassified to conform to Ind AS presentation requirements for the purposes of this note.

12. Previous Year’s Figures

As stated in Note 3.1, the Company has adopted Indian Accounting Standards with effect from 1 April 2017 with date of transition to Ind AS being 1 April 2016. Accordingly, previous year figures in the financial statements have been restated to Ind AS. Further, previous year''s figures have been regrouped / reclassified wherever necessary to correspond with the current year''s classification / disclosure.

13. Approval of Financial Statements

The Board of Directors of the Company has reviewed the realisable value of all the current assets and has confirmed that the value of such assets in the ordinary course of business will not be less that the value at which these are recognized in the financial statements. In addition, the Board has also confirmed the carrying value of the non-current assets in the financial statements. The Board, duly taking into account all the relevant disclosures made, has approved these financial statements in its meeting held on 28 May 2018.


Mar 31, 2017

1 CORPORATE INFORMATION

Dr. Agarwal’s Eye Hospital Limited (‘the Company’) was incorporated on April 22, 1994 and is primarily engaged in providing eye care and related services. As at March 31, 2017, the Company is operating in 23 locations in India. Dr. Agarwal’s Health Care Limited is the holding Company as at March 31, 2017.

2. SHARE CAPITAL

(Refer Notes (i) to (iv) below)

(i) Reconciliation of the number of shares and amount outstanding at the beginning and at the end of the reporting period :

(ii) Terms / rights attached to Equity Shares :

The Company has only one class of equity shares having a par value of Rs.10. Each holder is entitled to one vote per equity share. Dividends are paid in Indian Rupees. Dividend proposed by the Board of Directors, if any, is subject to the approval of the shareholders at the Annual General Meeting except in case of interim dividend. Repayment of capital will be in accordance with the terms of the Articles of Association and in proportion to the number of equity shares held.

The Board of Directors, at their meeting held on May 23, 2017, have proposed a final dividend of Rs.1.50 per equity share, aggregating to Rs.70.50 lakhs, for the year ended March 31, 2017. The dividend proposed by the Board of Directors is subject to the approval of shareholders at the ensuing Annual General Meeting.

(iii) Shares held by Dr. Agarwal’s Health Care Limited (Holding Company)

(i) During the year ended March 31, 2015, pursuant to the transition provisions prescribed in Schedule II to the Companies Act, 2013, the Company had fully depreciated the carrying value of assets, net of residual value, where the remaining useful life of the asset was determined to be Nil as on April 1, 2014, and had adjusted an amount of Rs.23.69 lakhs against the Surplus balance in the Statement of Profit and Loss under Reserves and Surplus. Further, during the previous year ended March 31, 2016, the Company had adjusted the deferred tax amount of Rs.7.69 lakhs arising on account of the above depreciation as a prior period adjustment to Surplus balance in the Statement of Profit and Loss under Reserves and Surplus.

Notes:

(i) The details of Security provided against the Term Loans are as follows:

- Extension of first charge on the entire Property, Plant and Equipment of the Company and first charge on the assets to be created out of the Term Loan.

- Extension of equitable mortagage on a property owned by Orbit International. - Extension of first charge on the entire Fixed assets of the company and first charge on the assets to be created out of the Term Loan.

- Pledge of 1,350,000 Shares of the Company held by Dr. Agarwal’s Health Care Limited. - Corporate Guarantee provided by Dr. Agarwal’s Health Care Limited and Orbit International.

- Personal Guarantees of Dr. Amar Agarwal, Dr. Athiya Agarwal, Dr. Adil Agarwal, Dr. Anosh Agarwal, Dr. Ashar Agarwal, Dr. Ashwin Agarwal, being the promoter and relatives of the promoter.

(ii) The loans are secured by hypothecation of respective vehicles financed by the Banks.

(iii) The loans are secured by hypothecation of surgical equipments.

(ii) The Cash credit facility availed by the Company as at March 31, 2017 is secured by the following:

- Hypothecation of all the current assets of the Company.

- Extension of equitable mortagage on a property owned by Orbit International.

- Pledge of 1,350,000 shares of the Company held by Dr. Agarwal’s Health Care Limited.

- Corporate Guarantee provided by Dr. Agarwal’s Health Care Limited and Orbit International.

- Personal Guarantees of Dr. Amar Agarwal, Dr. Athiya Agarwal, Dr. Adil Agarwal, Dr. Anosh Agarwal, Dr. Ashar Agarwal, Dr. Ashwin Agarwal, being the promoter and relatives of the promoter.

3. Capital Commitments

(a) (i) The estimated amount of contracts remaining to be executed on Capital Account, net of advances and not provided for is Rs.17.96 lakhs (Previous Year Rs.Nil).

(ii) Other commitments - Rs.Nil (Previous Year Rs.Nil)

4. Provision for Contingencies

The Company is carrying a provision for contingencies towards various claims against the Company not acknowledged as debts (Refer Note 30). The details are as follows:

Note:

Whilst the provision as at March 31, 2017 is considered as short term in nature, the actual outflow with regard to said matters depends on the exhaustion of remedies available under the law based on various developments. No recoveries are expected against the provision.

5. Foreign Currency Transactions

(a) Earnings in Foreign Currency (on Accrual Basis) - Rs.6.53 lakhs (Previous Year - Rs.Nil lakhs).

(b) Expenditure in Foreign Currency (on Accrual Basis):

6. Un-Hedged Foreign Currency Exposures as at the Balance Sheet date

The Company does not use any derivative instruments to hedge its foreign currency exposures. Details of unhedged foreign currency exposure are given below:

7. Corporate Social Responsibility

During the year, the Company incurred an aggregate amount of Rs.5.70 lakhs towards corporate social responsibility in compliance of Section 135 of the Companies Act 2013 read with relevant schedule and rules made thereunder. The details of the CSR spend are given below:

(i) Gross amount required to be spent by the Company during the year: Rs.5.70 Lakhs

(ii) Amount spent by the Company during the year on:

8. Employee Benefits

(a) The Company makes Provident Fund and Pension Fund contributions to defined contribution plans for qualifying employees. Under the Schemes, the Company is required to contribute a specified percentage of the payroll costs to fund the benefits. The Company recognised Rs.124.76 lakhs (Previous Year - Rs.121.81 lakhs) for Provident Fund contributions in the Statement of Profit and Loss. The contributions payable to these plans by the Company are at rates specified in the rules of the schemes.

(b) Compensated Absences

The Key Assumptions used in the computation of provision for long term compensated absences are as given below:

Gratuity

The Company has a funded gratuity scheme for covering its gratuity obligation. The gratuity liability has been recognised based on the actuarial valuation done as at the year end using the Projected Unit Credit method as given below:

Notes:

(i) The expected return on plan assets is as furnished by Life Insurance Corporation of India (LIC). The actual return on plan assets as furnished by LIC is Rs.13.42 lakhs.

(ii) The entire Plan Assets are managed by LIC, the Insurer. The details with respect to the composition of investments in the fair value of Plan Assets have not been disclosed in the absence of the necessary information.

(iii) The estimate of future salary increase takes into account inflation, seniority, promotion and other relevant factors.

(iv) Discount rate is based on the prevailing market yields of Indian Government Bonds as at the Balance Sheet date for the estimated term of the obligation.

(v) The expected contribution to be made in the next financial year is Rs.48.41 lakhs.

(vi) Experience Adjustments*

9. Segment Reporting

The Company is primarily engaged in the business of providing “Eye Care related sales and services”. All the activities of the Company revolve around the main business. As such there are no separate reportable segments as per AS-17 “Segmental Reporting”. Further, the Company does not have any separate geographic segment other than India. Accordingly, the figures appearing in these financial statements relate to “Eye Care related sales and services” segment.

10. Operating Lease

The Company has entered into non-cancellable operating lease agreements primarily for Hospitals and related retail outlets for Pharmacy and Optical sales. The lease period ranges for a period of 3 to 12 years. An amount of Rs.1,593.36 lakhs (Previous Year - Rs.1,456.96 lakhs) has been debited to the Statement of Profit and Loss towards lease rentals and other charges for the current year.

11. Disclosure of Specified Bank Notes (SBNs)

The disclosure in respect of the Ministry of Corporate Affairs’ notification dated March 30, 2017 with regard to Specified Bank Notes (SBNs) is as under:

12. Previous Year’s Figures

Previous year’s figures have been regrouped / reclassified wherever necessary to correspond with the current year’s classification / disclosure.

13. Approval of Financial Statements

The Board of Directors of the Company has reviewed the realisable value of all the current assets and has confirmed that the value of such assets in the ordinary course of business will not be less that the value at which these are recognized in the financial statements. In addition, the Board has also confirmed the carrying value of the non-current assets in the financial statements. The Board, duly taking into account all the relevant disclosures made, has approved these financial statements in its meeting held on May 23, 2017.


Mar 31, 2016

(ii) Terms / rights attached to Equity Shares :

The Company has only one class of equity shares having a par value of Rs. 10. Each holder is entitled to one vote per equity share. Dividends are paid in Indian Rupees. Dividend proposed by the Board of Directors, if any, is subject to the approval of the shareholders at the Annual General Meeting except in case of interim dividend. Repayment of capital will be in accordance with the terms of the Articles of Association and in proportion to the number of equity shares held.

During the year ended March 31, 2016, the amount of dividend recognized as distributions to equity shareholders is Rs. 0.80 per equity share (Previous Year Rs. 1.20 per equity share).

(i) During the previous year ended March 31, 2015, pursuant to the transition provisions prescribed in Schedule II to the Companies Act, 2013, the Company had fully depreciated the carrying value of assets, net of residual value, where the remaining useful life of the asset was determined to be Nil as on April 1, 2014, and had adjusted an amount of Rs. 23.69 lakhs against the Surplus balance in the Statement of Profit and Loss under Reserves and Surplus. Further, during the current year, the Company has adjusted the deferred tax amount of Rs. 7.69 lakhs arising on account of the above depreciation as a prior period adjustment to Surplus balance in the Statement of Profit and Loss under Reserves and Surplus.

(ii) Dividend is proposed to be distributed out of the profits available including the balance brought forward as at April 1, 2015.

Notes:

(i) The details of Security provided against the Term Loans are as follows:

- Extension of first charge on the entire Fixed assets of the Company and first charge on the assets to be created out of the Term Loan.

- Extension of equitable mortagage on a property owned by Orbit International.

- Pledge of 1,350,000 Shares of the Company held by Dr. Agarwal''s Health Care Limited.

- Corporate Guarantee provided by Dr. Agarwal''s Health Care Limited and Orbit International.

- Personal Guarantees of Dr. Amar Agarwal, Dr. Athiya Agarwal, Dr. Adil Agarwal, Dr. Anosh Agarwal, Dr. Ashar Agarwal, Dr. Ashwin Agarwal, being the promoter and relatives of the promoter.

(ii) The loans are secured by hypothecation of respective vehicles financed by the Banks.

(iii) The loans are secured by hypothecation of surgical equipments.

(ii) The Cash credit facility availed by the Company as at March 31, 2016 is secured by the following:

- Hypothecation of all the current assets of the Company.

- Extension of equitable mortagage on a property owned by Orbit International.

- Pledge of 1,350,000 shares of the Company held by Dr. Agarwal''s Health Care Limited.

- Corporate Guarantee provided by Dr. Agarwal''s Health Care Limited and Orbit International.

- Personal Guarantees of Dr. Amar Agarwal, Dr. Athiya Agarwal, Dr. Adil Agarwal, Dr. Anosh Agarwal, Dr. Ashar Agarwal, Dr. Ashwin Agarwal, being the promoter and relatives of the promoter.

(iii) Represents management consultancy income earned by the Company on rendering various consultancy services such as human resources, technical know-how, guidance in respect of procurements of machineries / consumables, development of Standard Operating Procedures and protocols, access to key employees, other administrative, Commercial and IT support, etc. provided to Dr. Agarwal''s Health Care Limited, the holding company, by the Company in accordance with the agreement. Refer Note 38(b).

*Dues to Micro and Small Enterprises have been determined to the extent such parties have been identified on the basis of information collected by the Management.

1. Capital Commitments

(a) (i) The estimated amount of contracts remaining to be executed on Capital Account, net of advances and not provided for is Rs. Nil (Previous Year Rs.211 Lakhs).

(ii) Other commitments - Rs. Nil (Previous Year Rs. Nil)

(i) Based on Professional Advice / Management''s assessment of all the above claims, the Company expects a favourable decision in respect of the above claims and hence no specific provision has been considered for the above claims. However, a general provision for Rs.9.62 lakhs has been made towards “Provision for Contingencies”. Refer Note 29.

(ii) The amounts shown above represent the best possible estimates arrived at on the basis of the available information. The uncertainties and possible reimbursement are dependent on the outcome of the various legal proceedings which have been initiated by the Company or the Claimants, as the case may be and, therefore, cannot be predicted accurately.

2. Foreign Currency Transactions

(a) Earnings in Foreign Currency (on Accrual Basis) - Rs. Nil (Previous Year - Rs. Nil lakhs).

3. The Company has incurred Rs. Nil (Previous Year - Rs.160 lakhs) as contribution towards Scientific Research-Eye Rep&rch Centre.

4. Corporate Social Responsibility

During the year, the Company incurred an aggregate amount of Rs.lakhs towards corporate social responsibility in compliance of Section 135 of the Companies Act 2013 read with relevant schedule and rules made there under. The details of the CSR spend are given below:

(i) Gross amount required to be spent by the Company during the year: Rs.9 Lakhs

5. Employee Benefits

(a) The Company makes Provident Fund and Pension Fund contributions to defined contribution plans for qualifying employees. Under the Schemes, the Company is required to contribute a specified percentage of the payroll costs to fund the benefits. The Company recognized Rs.121.81 lakhs (Previous Year - Rs.90.41 lakhs) for Provident Fund contributions in the Statement of Profit and Loss. The contributions payable to these plans by the Company are at rates specified in the rules of the schemes.

(i) The expected return on plan assets is as furnished by Life Insurance Corporation of India (LIC). The actual return on plan assets as furnished by LIC is Rs.13.56 lakhs.

(ii) The entire Plan Assets are managed by LIC, the Insurer. The details with respect to the composition of investments in the fair value of Plan Assets have not been disclosed in the absence of the necessary information.

(iii) The estimate of future salary increase takes into account inflation, seniority, promotion and other relevant factors.

(iv) Discount rate is based on the prevailing market yields of Indian Government Bonds as at the Balance Sheet date for the estimated term of the obligation.

(v) The expected contribution to be made in the next financial year is Rs.27.22 lakhs.

(vi) Experience Adjustments*

*Experience adjustments related to prior years have been disclosed based on the information to the extent available.

6. Segment Reporting

The Company has identified business segment as its primary segment and geographic segment as its secondary segment. Effective July 1, 2015, consequent to the change in the business oversight monitoring, the Management''s assessment of risks and rewards from the business operations has changed during the current year. The Management has brought all its operations under the single umbrella of “Eye Care related Sales and Services” and looks at the entire business as a single segment. Accordingly, the amounts appearing in the financial statements relate to this single primary business segment of “Eye Care related sales and services”.

(i) The Company accounts for costs incurred by / on behalf of the Related Parties based on the actual invoices / debit notes raised and accruals as confirmed by such related parties. The Related Parties have confirmed to the Management that as at March 31, 2016 and March 31, 2015, there are no further amounts payable to / receivable from them, other than as disclosed above. The Company incurs certain costs on behalf of other companies in the group. These costs have been allocated / recovered from the group companies on a basis mutually agreed to with the group companies.

(ii) Dr. Agarwal''s Health Care Limited has provided Corporate Guarantees amounting to Rs.3,555 lakhs to SBI for the loans taken by the Company. Further, 1,350,000 Equity Shares held by Dr. Agarwal''s Health Care Limited in the Company has been pledged as one of the collateral securities with SBI, for the loans taken by the Company to the extent of Rs.3,555 lakhs.

(iii) The Company has provided comfort letter to HDFC Bank in respect of the Equipment Loans and Cash Credit facility availed by the Dr. Agarwal''s Health Care Limited, the Holding Company.

(iv) Represents remuneration of Rs.3 lakhs per month, all inclusive by way of salary, allowances and perquisites paid to the Key Managerial Personnel, who has been appointed as the whole time director of the Company.

(v) Also Refer Note 5(i) and Note 7(ii).

7. Operating Lease

The Company has entered in to non-cancellable operating lease agreements primarily for Hospitals and related retail outlets for Pharmacy and Optical sales. The lease period ranges for a period of 3 to 12 years. An amount of Rs.1,605.58 lakhs (Previous Year Rs.1,459.33 lakhs) has been debited to the Statement of Profit and Loss towards lease rentals and other charges for the current year.

8. Previous Year’s Figures

Previous year''s figures have been regrouped / reclassified wherever necessary to correspond with the current year''s classification / disclosure.

9. Approval of Financial Statements

The Board of Directors of the Company has reviewed the realizable value of all the current assets and has confirmed that the value of such assets in the ordinary course of business will not be less that the value at which these are recognized in the financial statements. In addition, the Board has also confirmed the carrying value of the non-current assets in the financial statements. The Board, duly taking into account all the relevant disclosures made, has approved these financial statements in its meeting held on May 19, 2016.


Mar 31, 2015

1) Corporate Information:

Dr. Agarwal's Eye Hospital Limited ('the Company') was incorporated on April 22, 1994 under the provisions of Companies Act, 1956. The Company is primarily engaged in running, owning and managing eye care hospitals, Opticals, Pharmacy along with various other objectives like rendering hospital services in all branches of medical sciences both in India, carrying out medical research activities, etc. As at March 31, 2015, the Company is operating with 21 branches and one main hospital in India.

As on March 31, 2015, Dr.Agarwal's Health Care Limited is holding 71.75% of the Company's Equity share capital and has the ability to control its operating and financial policies.

2. Earnings in Foreign currency towards Consultancy Services during the year amounts to Rs.140.82 Lacs (P.Y. Rs.23.36 Lacs)

3. The information required to be disclosed under the Micro, Small and Medium Enterprises Development (MSMED) Act 2006 has been determined to the extent such parties have been identified on the basis of information available with the Company. There has been no overdues to parties on account of principal amount and / or interest and accordingly no additional disclosures have been made.

4. Deferred Tax Asset has been recognized for the current year for Rs.48.59 Lacs and pertaining to prior years for Rs. 215.28 Lacs as there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized. .

5. Impairment of Assets

As per the assessment conducted by the Company as at March 31,2015, there are no indications that the relevant assets have suffered an impairment loss. (P.Y. Rs.1.94 Lacs)

6. The CIF value of Import of Equipment during the year is Rs.299.00 Lacs. (P.Y. Rs.Nil)

7. Disclosure in respect of Leases pursuant to Accounting Standard (AS 19) "Leases":

The Company has taken various commercial premises under cancellable operating leases. These lease agreements are normally renewed on expiry. The Lease rental expense incurred in respect of operating leases is Rs.1,459.33 lacs. (P.Y. Rs.1,378.82 lacs)

8. Capital Commitments

Estimated amount of contracts remaining to be executed on capital account and not provided for net of advances is Rs.211.00 Lacs. (P.Y. Rs.57.88 Lacs)

9. The Company has incurred Rs.160.00 Lacs as contribution towards Scientific Research of Eye Research Centre during the year (P.Y. Rs.240.08 Lacs)

10. Employee Benefits

a) The Company makes Provident Fund and Pension Fund contributions to defined contribution plans for qualifying employees. Under the Schemes, the Company is required to contribute a specified percentage of the payroll costs to fund the benefits. The Company recognized Rs.90.41 Lacs (Previous Year - Rs.88.18 Lacs) for Provident Fund contributions in the Statement of Profit and Loss. The contributions payable to these plans by the Company are at rates specified in the rules of the schemes.

Notes:

1) The expected return on plan assets is as furnished by Life Insurance Corporation of India (LIC).

2) The entire Plan Assets are managed by LIC, the Insurer. The details with respect to the composition of investments in the fair value of Plan Assets have not been disclosed in the absence of the necessary information.

3) The estimate of future salary increase takes into account inflation, seniority, promotion and other relevant factors.

4) Discount rate is based on the prevailing market yields of Indian Government Bonds as at the Balance Sheet date for the estimated term of the obligation.

11. Related Party Disclosures

A) Related parties and their relationship

1. Holding Company

- Dr.Agarwal's Health Care Limited.

2. Enterprises in which Individuals referred below in 3 have significant influence

- Orbit International

- Orbit Health Care Services Limited, Mauritius

- Dr.Agarwal's Eye Institute

3. Key Management Personnel

- Dr.Amar Agarwal - Chairman and Managing Director

- Dr.Athiya Agarwal - Director

- Dr.Adil Agarwal - Director

- Dr.Anosh Agarwal - Director

- Mr. S. Ramanujam - Company Secretary

- Mr. R. Sabesan - Chief Financial Officer

- Related Party relationships are as identified by the Management and relied upon by the Auditors.

12. Un-Hedged Foreign Currency Exposure as at the Balance Sheet date

The Company does not use any derivative instruments to hedge its foreign currency exposures. Further, the Company has unhedged foreign currency receivable exposure of Rs.77.31 Lacs as at March 31, 2015. (Rs.53.98 Lacs as at March 31,2014)

13. Previous year figures have been recast / restated to conform to the classification of the current year.


Mar 31, 2014

1) Corporate Information:

Dr. Agarwal''s Eye Hospital Limited (''the Company'') was incorporated on April 22, 1994 under the provisions of Companies Act, 1956. The Company is primarily engaged in running, owning and managing eye care hospitals, Opticals, Pharmacy along with various other objectives like rendering hospitality services in all branches of medical sciences both in India and abroad, carrying out medical research activities, etc. As at March 31,2014, the Company is operating with 22 branches and one main hospital in Tamilnadu.

As on March 31, 2014, Dr.Agarwal''s Health Care Limited owned 71.75% of the Company''s Equity share capital and has the ability to control its operating and financial policies.

2. Expenditure incurred in foreign currency during the year is Rs. Nil (P.Y. Rs.14.10 Lacs).

3. Earnings in Foreign currency towards Consultancy Services and other Surgeries during the year amounts to Rs.23.36 Lacs (P.Y. Rs.178.46 Lacs)

4. The information required to be disclosed under the Micro, Small and Medium Enterprises Development Act 2006 has been determined to the extent such parties have been identified on the basis of information available with the company. There has been no overdues to parties on account of principal amount and / or interest and accordingly no additional disclosures have been made.

5. Deferred Tax Asset has not been recognized as there is no reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized.

6. Impairment of Assets

On a review as required by AS 28, the amount of Impairment loss charged to Profit & Loss A/c during the F.Y.2013-14 is Rs. 1.94 Lacs (P.Y. Rs. 2.38 Lacs)

7. Intangible Assets

As per AS 26, 1/10th of Goodwill amounting to Rs.23.61 Lacs has been amortized during the year. (P.Y.Rs.22.86 Lacs)

8. The CIF value of Imports during the year is Rs. Nil. (P.Y. Nil)

9. Disclosure in respect of Leases pursuant to Accounting Standard (AS 19) "Leases":

The Company has taken various commercial premises under cancellable operating leases. These lease agreements are normally renewed on expiry. The Lease rental expense incurred in respect of operating leases is Rs. 1378.82 lacs. (P.Y. Rs. 1323.60 lacs)

10. Capital Commitments

Estimated amount of contracts remaining to be executed on capital account and not provided for net of advances is Rs.57.88 Lacs. (P.Y. Rs.20.57 Lacs)

11. The Company has incurred Rs.239.68 Lacs as contribution towards Scientific Research of Eye Research Centre during the year (P.Y. Rs. 200.41Lacs)

12. The overdue Trade Receivables and Advance Recoverable from others as on 31/03/2014 amounts to Rs. 1.84 Crore and Rs.80.34 Lakhs respectively. The Company is in the process of obtaining confirmation of these dues and also taking steps for recovering the same.

13. Segment reporting made in accordance with Accounting Standard AS 17 with business as the primary segment

14. Related Party Disclosures

A) Related parties and their relationship

1. Holding Company

Dr.Agarwal''s Health Care Limited.

2. Group Companies with whom the company has transactions

Orbit International

Orbit Health Care Services Limited, Mauritius

Dr.Agarwal''s Eye Institute

Dr.Agarwal''s Opticals Limited

3. Key Management Personnel

Dr.Amar Agarwal

Dr.Athiya Agarwal

Dr.Adil Agarwal

Dr.Anosh Agarwal

* Related Party relationships are as identified by the Management and relied upon by the Auditors.

15. Contingent Liabilities (Rs. in Lacs)

Particulars As at March 31, 2014 As at March 31, 2013

Claims against the Company not acknowledged as debt Nil Nil

Income Tax demands 83.46 67.34

Indirect Tax demands 30.59 Nil

16. Un-Hedged Foreign Currency Exposure as at the Balance Sheet date

The Company does not use any derivative instruments to hedge its foreign currency exposures. Further, the Company does not have unhedged foreign currency balances as at March 31, 2014 and March 31, 2013.

17. Previous year figures have been recasted/restated to conform to the classification of the current year.


Mar 31, 2013

1. Expenditure incurred in foreign currency towards Foreign travel, Subscription for magazines, Membership fees during the year amounts to Rs.14,09,719/- (P.Y. Rs. 4,16,735/-).

2. Earnings in Foreign currency towards Consultancy Services and other Surgeries during the year amounts to Rs. 1,78,46,233/- (P.Y. Rs. 1,48,43,470/-)

3. The CIF value of Machinery imported during the year is Rs.Nil /- (RY. Rs. 1,73,47,762/-).

4. The information required to be disclosed under the Micro, Small and Medium Enterprises Development Act 2006 has been determined to the extent such parties have been identified on the basis of information available with the company. There has been no over dues to parties on account of principal amount and / or interest and accordingly no additional disclosures have been made.

5. Deferred Tax Asset has not been recognized as there is no reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized.

6. Impairment of Assets

On a review as required by AS 28, the amount of Impairment loss charged to Profit & Loss A/c during the F.Y.2012 -13 is Rs.2,37,575/- (P.Y Rs. 1,91,380/-)

7. Intangible Assets

As per AS 26, 1/10th of Goodwill amounting to Rs.22,85,992/- has been amortized during the year. (P.YRs.22,83,328/-)

8. Claims against the Company not acknowledged as debt is Rs. Nil.

9. Capital Commitments

Estimated amount of contracts remaining to be executed on capital account and not provided for Net of Advances is Rs. 20,57,214/- (P.Y Rs. Nil /-)

10. The Company has incurred Rs.2,00,40,946/- as contribution towards Scientific Research of Eye Research Centre during the year (Previous Year : Rs. Nil)

11. Related Party Disclosures

A) Related parties and their relationship

1. Holding Company

- Dr.Agarwal''s Health Care Limited.

2. Group Companies with whom the Company has transactions

- Orbit International

- Dr.Agarwal''s Eye Institute

- Senses Pharmaceuticals Limited

- Dr.Agarwal''s Opticals Limited

3. Key Management Personnel 3> Dr.Amar Agarwal

- Dr. Athiya Agarwal <$> Dr. Adil Agarwal

12. Previous year figures have been recasted/restated to conform to the classification of the current year.


Mar 31, 2012

1) Expenditure incurred in foreign currency towards Foreign travel, Subscription for magazines, Membership fees during the year amounts to Rs.4,16,735/- (P.Y. Rs. 34,81,750/-)

2) Earnings in Foreign currency towards Consultancy Services and other Surgeries during the year amounts to Rs.1,48,43,470/- (P.Y. Rs. 11,87,013/-)

3) The CIF value of Machinery imported during the year is Rs.1,73,47,762/- (P.Y. Rs.34,27,734/-).

4) Total number of Managing and Whole-time Directors is Four. Remuneration drawn for the F.Y.2011 - 12 is Rs.1,14,50,000/- (P.Y Rs.1,21,00,000/-).

5) The information required to be disclosed under the Micro, Small and Medium enterprises Development Act 2006 has been determined to the extent such parties have been identified on the basis of information available with the Company. There has been no over dues to parties on account of principal amount and / or interest and accordingly no additional disclosures have been made.

6) Deferred Tax Asset has not been recognized as there is no reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized.

7) Impairment of Assets

On a review as required by AS 28, the amount of Impairment loss charged to Profit & Loss A/c during the F.Y.2011 -12 is Rs. 1,91,380/- (P.Y Rs.36,02,939/-)

8) Intangible Assets

As per AS 26, 1/10th of Goodwill amounting to Rs.22,83,328/- has been amortized during the year. (P.Y.Rs.22,83,328/-)

9) Claims against the Company not acknowledged as debt is Rs. Nil

10. These financial statements have been prepared in the format prescribed by the Revised Schedule VI to the Companies Act, 1956. Previous year figures have been recasted/ restated to confirm to the classification of the current year.


Mar 31, 2010

1. Previous year figures have been regrouped wherever necessary.

2. Expenditure incurred in foreign currency towards foreign travel, subscription for magazines, membership fees, repairs & maintenance, consumables and advertisement during the year amounts to Rs.25,71,653/ - (P.Y. Rs.34,45,200/- ).

3. The CIF value of Machineries imported during the year is Rs.1,34,22,286 /- (P.Y. Rs.1,16,54,691/-).

4. Total number of Managing and Whole-time Directors is Three.

Remuneration drawn Rs. 78,75,000/- (Minimum remuneration)

Since the remuneration is within the limits and in accordance with Schedule XIII, computation of remuneration under sec. 198 and sec 349 of Companies Act, 1956 has not been given.

5. The information required to be disclosed under the Micro, Small and Medium enterprises Development Act 2006 has been determined to the extent such parties have been identified on the basis of information available with the company. There has been no over dues to parties on account of principal amount and / or interest and accordingly no additional disclosures have been made.

6. Deferred Tax Asset has not been recognized as there is no reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized.

7. Impairment of Assets

During the year on a review as required by AS 28, the amount of Impairment loss charged to Profit & Loss A/c is Rs.30,13,536/- 10. Intangible Assets

As per AS 26, 1/10th of Goodwill amounting to Rs.21,85,412/- has been amortized during the year.

8. Due to change in accounting policy, the improvements made to Leasehold Buildings during the year amounting to Rs.1,91,39,316/- has been capitalized. Till last year, such expenses were charged to Profit & Loss A/c as Interior Decoration Expenses.

9. Claims against the company not acknowledged as debt is Rs. Nil.

Get Instant News Updates
Enable
x
Notification Settings X
Time Settings
Done
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X